Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors

HMBD-002 accomplishes this without depleting VISTA expressing immune cells that play important roles in the immune response.